Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Rheumatoid Arthritis
NCT07864688Phase 2Not yet recruiting
- Sponsor
- Al-Azhar University
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin, empagliflozin in rheumatoid arthritis (RA), sponsored by Al-Azhar University. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07864688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07864688.